HZ-166 | CAS#612527-56-7 | Positive GABAA receptor modulator

MedKoo Cat#: 530331 | Name: HZ166

Description:

WARNING: This product is for research use only, not for human or veterinary use.

HZ-166 is a Positive GABAA receptor modulator and a GABAA receptor subtype-selective benzodiazepine site ligand. HZ166 is antihyperalgesic in mouse models of inflammatory and neuropathic pain. Diminished GABAergic and glycinergic inhibition in the spinal dorsal horn contributes significantly to chronic pain of different origins. Accordingly, pharmacological facilitation of GABAergic inhibition by spinal benzodiazepines (BDZs) has been shown to reverse pathological pain in animals as well as in human patients.

Chemical Structure

HZ166

CAS#612527-56-7

Theoretical Analysis

MedKoo Cat#: 530331

Name: HZ166

CAS#: 612527-56-7

Chemical Formula: C21H16N4O2

Exact Mass: 356.1273

Molecular Weight: 356.39

Elemental Analysis: C, 70.77; H, 4.53; N, 15.72; O, 8.98

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

HZ-166; HZ 166; HZ166.

IUPAC/Chemical Name

ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate

InChi Key

ZSEDMNMFODMQRD-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H16N4O2/c1-3-14-8-9-17-15(11-14)19(16-7-5-6-10-22-16)23-12-18-20(21(26)27-4-2)24-13-25(17)18/h1,5-11,13H,4,12H2,2H3

SMILES Code

O=C(C1=C2N(C=N1)C3=CC=C(C#C)C=C3C(C4=NC=CC=C4)=NC2)OCC

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 356.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Yuan NY, Poe MM, Witzigmann C, Cook JM, Stafford D, Arnold LA. Characterization of GABA(A) receptor ligands with automated patch-clamp using human neurons derived from pluripotent stem cells. J Pharmacol Toxicol Methods. 2016 Nov - Dec;82:109-114. doi: 10.1016/j.vascn.2016.08.006. PubMed PMID: 27544543; PubMed Central PMCID: PMC5116268. 2: Paul J, Yévenes GE, Benke D, Di Lio A, Ralvenius WT, Witschi R, Scheurer L, Cook JM, Rudolph U, Fritschy JM, Zeilhofer HU. Antihyperalgesia by α2-GABAA receptors occurs via a genuine spinal action and does not involve supraspinal sites. Neuropsychopharmacology. 2014 Jan;39(2):477-87. doi: 10.1038/npp.2013.221. PubMed PMID: 24045508; PubMed Central PMCID: PMC3870792. 3: Fischer BD, Teixeira LP, van Linn ML, Namjoshi OA, Cook JM, Rowlett JK. Role of gamma-aminobutyric acid type A (GABAA) receptor subtypes in acute benzodiazepine physical dependence-like effects: evidence from squirrel monkeys responding under a schedule of food presentation. Psychopharmacology (Berl). 2013 May;227(2):347-54. doi: 10.1007/s00213-013-2975-2. PubMed PMID: 23354533; PubMed Central PMCID: PMC3637862. 4: Chen Q, Yim PD, Yuan N, Johnson J, Cook JM, Smith S, Ionescu-Zanetti C, Wang ZJ, Arnold LA, Emala CW. Comparison of cell expression formats for the characterization of GABA(A) channels using a microfluidic patch clamp system. Assay Drug Dev Technol. 2012 Aug;10(4):325-35. doi: 10.1089/adt.2011.415. PubMed PMID: 22574655; PubMed Central PMCID: PMC3419985. 5: Fischer BD, Atack JR, Platt DM, Reynolds DS, Dawson GR, Rowlett JK. Contribution of GABA(A) receptors containing α3 subunits to the therapeutic-related and side effects of benzodiazepine-type drugs in monkeys. Psychopharmacology (Berl). 2011 May;215(2):311-9. doi: 10.1007/s00213-010-2142-y. PubMed PMID: 21190016; PubMed Central PMCID: PMC3097109. 6: Di Lio A, Benke D, Besson M, Desmeules J, Daali Y, Wang ZJ, Edwankar R, Cook JM, Zeilhofer HU. HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain. Neuropharmacology. 2011 Mar;60(4):626-32. doi: 10.1016/j.neuropharm.2010.11.026. PubMed PMID: 21145329; PubMed Central PMCID: PMC3566476. 7: Fischer BD, Licata SC, Edwankar RV, Wang ZJ, Huang S, He X, Yu J, Zhou H, Johnson EM Jr, Cook JM, Furtmüller R, Ramerstorfer J, Sieghart W, Roth BL, Majumder S, Rowlett JK. Anxiolytic-like effects of 8-acetylene imidazobenzodiazepines in a rhesus monkey conflict procedure. Neuropharmacology. 2010 Dec;59(7-8):612-8. doi: 10.1016/j.neuropharm.2010.08.011. PubMed PMID: 20727364; PubMed Central PMCID: PMC2963662.